益生菌治疗非酒精性脂肪性肝病的相关进展研究
Research Progress of Probiotics in the Treatment of Nonalcoholic Fatty Liver Disease
DOI: 10.12677/ACM.2022.1281047, PDF,   
作者: 周厚法*, 孙 琦：青海大学研究生院，青海 西宁；马颖才：青海省人民医院消化科，青海 西宁
关键词: 非酒精性脂肪性肝病；益生菌；抗生素；Nonalcoholic Fatty Liver Disease； Probiotics； Antibiotic
摘要: 非酒精性脂肪肝(NAFLD)是一种代谢相关性，以肝细胞脂肪变性为主要特征的疾病。随着近几十年来人民生活水平的提高，在我国NAFLD的患病率达到了6%~27%，已取代慢性乙型肝炎成为我国第一大慢性肝病，且目前正朝着低龄化和迅速上升的态势发展，严重威胁人类健康。至今为止，除了控制血糖和血脂以及减肥等针对原发病和危险因素的治疗方式外，暂无明确的药物治疗方法。而近年来由于对肠–肝轴的认识越来越深，以及对肠道菌群在NAFLD发生机理中的作用了解越来越多，益生菌防治NAFLD的研究也随之增多。本综述重点对肠道益生菌的新疗法在NAFLD治疗中的研究进展进行总结。
Abstract: Nonalcoholic fatty liver disease (NAFLD) is a metabolic related disease characterized by hepatocyte steatosis. With the improvement of people’s living standards in recent decades, the prevalence of NAFLD in China has reached 6%~27%, which has replaced chronic hepatitis B and become the largest chronic liver disease in China. At present, it is developing towards younger age and rising rapidly, which has seriously threatened human health. So far, there is no clear drug treatment ex-cept for the treatment of primary disease and risk factors such as blood glucose and blood lipid control and weight loss. In recent years, due to the deeper understanding of the gut liver axis and the role of intestinal flora in the pathogenesis of NAFLD, the research on the prevention and treat-ment of NAFLD by probiotics has also increased. This review focuses on the research progress of new therapies of intestinal probiotics in the treatment of NAFLD.
文章引用：周厚法, 马颖才, 孙琦. 益生菌治疗非酒精性脂肪性肝病的相关进展研究[J]. 临床医学进展, 2022, 12(8): 7249-7255. https://doi.org/10.12677/ACM.2022.1281047

参考文献

[1] 施军平, 范建高. 脂肪性肝病诊疗规范化的专家建议(2019年修订版) [J]. 实用肝脏病杂志, 2019, 22(6): 787-792.
[2] Roychowdhury, S., Selvakumar, P.C. and Cresci, G.A.M. (2018) The Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease. Medical Sciences (Basel, Switzerland), 6, Article No. 47. [Google Scholar] [CrossRef] [PubMed]
[3] Ma, J., et al. (2017) Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanisms and Therapy. Nutrients, 9, Article No. 1124. [Google Scholar] [CrossRef] [PubMed]
[4] 中华医学会内分泌学分会. 非酒精性脂肪性肝病与相关代谢紊乱诊疗共识(第二版) [J]. 临床肝胆病杂志, 2018, 34(10): 2103-2108.
[5] Kefala, G. and Tziomalos, K. (2019) Apoptosis Signal-Regulating Kinase-1 as a Therapeutic Target in Nonalcoholic Fatty Liver Disease. Expert Review of Gastroenter-ology & Hepatology, 13, 189-191. [Google Scholar] [CrossRef] [PubMed]
[6] Safari, Z. and Gérard, P. (2019) The Links between the Gut Microbiome and Non-Alcoholic Fatty Liver Disease (NAFLD). Cellular and Molecular Life Sciences: CMLS, 76, 1541-1558. [Google Scholar] [CrossRef] [PubMed]
[7] Jasirwan, C.O.M., et al. (2016) The Role of the Gut Microbiota in NAFLD. Nature Reviews Gastroenterology & Hepatology, 13, 412-425. [Google Scholar] [CrossRef] [PubMed]
[8] Jandhyala, S.M., Talukdar, R., Subramanyam, C., et al. (2015) Role of the Normal Gut Microbiota. World Journal of Gastroenterology, 21, 8787-8803. [Google Scholar] [CrossRef] [PubMed]
[9] Ley, R.E., Turnbaugh, P.J., Klein, S., et al. (2006) Microbial Ecolo-gy: Human Gut Microbes Associated with Obesity. Nature, 444, 1022-1023. [Google Scholar] [CrossRef] [PubMed]
[10] Wang, Z., Klipfell, E., Bennett, B.J., et al. (2011) Gut Flora Metabolism of Phosphatidylcholine Promotes Cardiovascular Disease. Nature, 472, 57-63. [Google Scholar] [CrossRef] [PubMed]
[11] Ley, R.E. (2010) Obesity and the Human Microbiome. Current Opinion in Gastroenterology, 26, 5-11. [Google Scholar] [CrossRef] 
[12] Qin, J., Li, Y., Cai, Z., et al. (2012) A Metagenome-Wide Association Study of Gut Microbiota in Type 2 Diabetes. Nature, 490, 55-60. [Google Scholar] [CrossRef] [PubMed]
[13] Murphy, E.F., Cotter, P.D., Hogan, A., et al. (2013) Divergent Metabolic Outcomes Arising from Targeted Manipulation of the Gut Microbiota in Diet-Induced Obesity. Gut, 62, 220-226. [Google Scholar] [CrossRef] [PubMed]
[14] De Minicis, S., Rychlicki, C., Agostinelli, L., et al. (2014) Dysbiosis Contributes to Fibrogenesis in the Course of Chronic Liver Injury in Mice. Hepatology, 59, 1738-1749. [Google Scholar] [CrossRef] [PubMed]
[15] Le Roy, T., Llopis, M., Lepage, P., et al. (2013) Intestinal Microbiota De-termines Development of Non-Alcoholic Fatty Liver Disease in Mice. Gut, 62, 1787-1794. [Google Scholar] [CrossRef] [PubMed]
[16] Macpherson, A.J., et al. (2016) The Liver at the Nexus of Host-Microbial Interactions. Cell Host & Microbe, 20, 561-571. [Google Scholar] [CrossRef] [PubMed]
[17] Li, F., Duan, K., Wang, C., et al. (2016) Probiotics and Alcoholic Liver Disease: Treatment and Potential Mechanisms. Gastroenterology Research and Practice, 2016, Article ID: 5491465. [Google Scholar] [CrossRef] [PubMed]
[18] Brown, C.T., Sharon, I., Thomas, B.C., et al. (2013) Genome Resolved Analysis of a Premature Infant Gut Microbial Community Reveals a Varibaculum Cambriense Genome and a Shift towards Fermentation-Based Metabolism during the Third Week of Life. Microbiome, 1, 30. [Google Scholar] [CrossRef] [PubMed]
[19] The Human Microbiome Project Consortium (2012) Structure, Func-tion and Diversity of the Healthy Human Microbiome. Nature, 486, 207-214. [Google Scholar] [CrossRef] [PubMed]
[20] Paolella, G., Mandato, C., Pierri, L., et al. (2014) Gut-Liver Axis and Probiotics: Their Role in Non-Alcoholic Fatty Liver Disease. World Journal of Gastroenterology, 20, 15518-15531. [Google Scholar] [CrossRef] [PubMed]
[21] Miura, K., Kodama, Y., Inokuchi, S., et al. (2010) Toll-Like Re-ceptor 9 Promotes Steatohepatitis by Induction of Interleukin-1beta in Mice. Gastroenterology, 139, 323-234.e7. [Google Scholar] [CrossRef] [PubMed]
[22] Krajmalnik-Brown, R., et al. (2012) Effects of Gut Microbes on Nutrient Absorption and Energy Regulation. Nutrition in Clinical Practice: Official Publication of the American Society for Parenteral and Enteral Nutrition, 27, 201-214. [Google Scholar] [CrossRef] [PubMed]
[23] Bäckhed, F., et al. (2004) The Gut Microbiota as an Environmen-tal Factor That Regulates Fat Storage. Proceedings of the National Academy of Sciences of the United States of America, 101, 15718-15723. [Google Scholar] [CrossRef] [PubMed]
[24] Ge, H., et al. (2008) Activation of G Protein-Coupled Receptor 43 in Adipocytes Leads to Inhibition of Lipolysis and Suppression of Plasma Free Fatty Acids. Endocrinology, 149, 4519-4526. [Google Scholar] [CrossRef] [PubMed]
[25] Lorenzo-Zúñiga, V., et al. (2003) Oral Bile Acids Reduce Bacterial Overgrowth, Bacterial Translocation, and Endotoxemia in Cirrhotic Rats. Hepatology (Baltimore, Md), 37, 551-557. [Google Scholar] [CrossRef] [PubMed]
[26] Ogata, Y., Nishi, M., Nakayama, H., et al. (2003) Role of Bile in Intestinal Barrier Function and Its Inhibitory Effect on Bacterial Translocation in Obstructive Jaundice in Rats. Journal of Surgical Research, 115, 18-23. [Google Scholar] [CrossRef] 
[27] Kazankov, K., Jørgensen, S.M.D., Thomsen, K.L., et al. (2019) The Role of Macrophages in Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Nature Reviews Gastroenterology & Hepatology, 16, 145-159. [Google Scholar] [CrossRef] [PubMed]
[28] Corbin, K.D. and Zeisel, S.H. (2012) Choline Metabolism Pro-vides Novel Insights into Nonalcoholic Fatty Liver Disease and Its Progression. Current Opinion in Gastroenterology, 28, 159-165. [Google Scholar] [CrossRef] 
[29] Zhu, L., Baker, S.S., Gill, C., et al. (2013) Characterization of Gut Microbiomes in Nonalcoholic Steatohepatitis (NASH) Patients: A Connection between Endogenous Alcohol and NASH. Hepatology, 57, 601-609. [Google Scholar] [CrossRef] [PubMed]
[30] Rao, R.K., Seth, A. and Sheth, P. (2004) Recent Advances in Alcoholic Liver Disease I. Role of Intestinal Permeability and Endotoxemia in Alcoholic Liver Disease. The American Journal of Physiology-Gastrointestinal and Liver Physiology, 286, G881-G884. [Google Scholar] [CrossRef] [PubMed]
[31] Ferolla, S.M., Armiliato, G.N., Couto, C.A., et al. (2015) Probiotics as a Complementary Therapeutic Approach in Nonalcoholic Fatty Liver Disease. World Journal of Hepatology, 7, 559-565. [Google Scholar] [CrossRef] [PubMed]
[32] Tarantino, G. and Finelli, C. (2015) Systematic Review on In-tervention with Prebiotics/Probiotics in Patients with Obesity-Related Nonalcoholic Fatty Liver Disease. Future Microbi-ology, 10, 889-902. [Google Scholar] [CrossRef] [PubMed]
[33] Madrid, A.M., Hurtado, C., Venegas, M., et al. (2001) Long-Term Treatment with Cisapride and Antibiotics in Liver Cirrhosis: Effect on Small Intestinal Motility, Bacterial Overgrowth, and Liver Function. American Journal of Gastroenterology, 96, 1251-1255. [Google Scholar] [CrossRef] [PubMed]
[34] Janssen, A.W.F., Houben, T., Katiraei, S., et al. (2017) Modulation of the Gut Microbiota Impacts Nonalcoholic Fatty Liver Disease: A Potential Role for Bile Acids. Journal of Lipid Research, 58, 1399-1416. [Google Scholar] [CrossRef] 
[35] Davani-Davari, D., Negahdaripour, M., Karimzadeh, I., et al. (2019) Prebiotics: Definition, Types, Sources, Mechanisms, and Clinical Applications. Foods, 8, 92. [Google Scholar] [CrossRef] [PubMed]
[36] Pachikian, B.D., Essaghir, A., Demoulin, J.B., et al. (2013) Prebiotic Approach Alleviates Hepatic Steatosis: Implication of Fatty Acid Oxidative and Cholesterol Synthesis Pathways. Molec-ular Nutrition & Food Research, 57, 347-359. [Google Scholar] [CrossRef] [PubMed]
[37] Ferolla, S.M., Couto, C.A., Costa-Silva, L., et al. (2016) Beneficial Effect of Synbiotic Supplementation on Hepatic Steatosis and Anthropometric Parameters, But Not on Gut Permeability in a Population with Nonalcoholic Steatohepatitis. Nutrients, 8, 397. [Google Scholar] [CrossRef] [PubMed]
[38] Famouri, F., Shariat, Z., Hashemipour, M., et al. (2017) Effects of Probi-otics on Nonalcoholic Fatty Liver Disease in Obese Children and Adolescents. Journal of Pediatric Gastroenterology and Nutrition, 64, 413-417. [Google Scholar] [CrossRef] 
[39] Okubo, H., Sakoda, H., Kushiyama, A., et al. (2013) Lac-tobacillus casei Strain Shirota Protects against Nonalcoholic Steatohepatitis Development in a Rodent Model. The Amer-ican Journal of Physiology-Gastrointestinal and Liver Physiology, 305, G911-G918. [Google Scholar] [CrossRef] [PubMed]
[40] Xin, J., Zeng, D., Wang, H., et al. (2014) Preventing Non-Alcoholic Fatty Liver Disease through Lactobacillus johnsonii BS15 by Attenuating Inflammation and Mitochondrial Injury and Improving Gut Environment in Obese Mice. Applied Microbiology and Biotechnology, 98, 6817-6829. [Google Scholar] [CrossRef] [PubMed]
[41] Nobili, V., Mosca, A., Alterio, T., et al. (2019) Fighting Fatty Liver Diseases with Nutritional Interventions, Probiotics, Symbiotics, and Fecal Microbiota Transplantation (FMT). Ad-vances in Experimental Medicine and Biology, 1125, 85-100. [Google Scholar] [CrossRef] [PubMed]
[42] Liang, Y., Lin, C., Zhang, Y., et al. (2018) Probiotic Mixture of Lactobacillus and Bifidobacterium Alleviates Systemic Adipos-ity and Inflammation in Non-Alcoholic Fatty Liver Disease Rats through Gpr109a and the Commensal Metabolite Butyr-ate. Inflammopharmacology, 26, 1051-1055. [Google Scholar] [CrossRef] [PubMed]
[43] Zhou, D., Pan, Q., Shen, F., et al. (2017) Total Fecal Microbiota Transplantation Alleviates High-Fat Diet-Induced Steatohepatitis in Mice via Beneficial Regulation of Gut Microbiota. Scientific Reports, 7, Article No. 1529. [Google Scholar] [CrossRef] [PubMed]

为你推荐